Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.
Reid Merryman, MD
Advertisement
Articles by Reid Merryman, MD
Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.
Reid Merryman, MD, on Study Findings Investigating Prognostic Value of ctDNA for Patients with DLBCL
Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.
Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.
Advertisement
Latest Updated Articles
Reid Merryman, MD, on Pre- and Post-Transplant Data for Patients with DLBCLPublished: January 23rd 2021 | Updated:
Reid Merryman, MD, Discusses Autologous Stem Cell Transplantation for Patients with DLBCLPublished: January 13th 2021 | Updated:
Reid Merryman, MD, on Study Findings Investigating Prognostic Value of ctDNA for Patients with DLBCLPublished: January 21st 2021 | Updated:
Reid Merryman, MD, on Potential Clinical Designs with MRD-Guidance for Patients with DLBCLPublished: January 25th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel Cancer Vaccine Improves OS vs SOC in Newly Diagnosed GBM
2
FDA Gives Traditional Approval to Pirtobrutinib in CLL/SLL
3
FDA Approves Novel Blood-Based Prostate Cancer Test for Elevated PSA Levels
4
Delving Into the Current State of Clinical Practice in SCLC
5
